B.Riley FBR analyst Mayank Mamtani reiterated a Buy rating on Vaxart (NASDAQ:VXRT) Inc on Tuesday, setting a price target of 22, which is approximately 79.01% above the present share price of $12.29.
Mamtani expects Vaxart Inc to post earnings per share (EPS) of -$0.02 for the third quarter of 2020.
The current consensus among 3 TipRanks analysts is for a Strong Buy rating of shares in Vaxart, with an average price target of $11.67.
The analysts price targets range from a high of $22 to a low of $6.
In its latest earnings report, released on 03/31/2020, the company reported a quarterly revenue of $2.9 million and a net profit of -$630 thousand. The company's market cap is $1.22 billion.
According to TipRanks.com, B.Riley FBR analyst Mayank Mamtani is currently ranked with 5 stars on a 0-5 stars ranking scale, with an average return of 19.6% and a 49.48% success rate.
Biota Holdings Ltd. operates as an anti infective drug development firm. The company was founded on October 2, 1985 and is headquartered in Notting Hil, Australia.